Evidence map›Paper›PMID 41948549›Full record

ArticleInternational journal of microbiology2026

Gut Microbiota Diversity and Function in Adults With Type 2 Diabetes, Alzheimer's Disease, and Both Conditions.

Alexis M Rodríguez-Rosas, Diana L Baldenebro-Félix, Jesús M Peréz-Villarreal, Jaime García-Mena, Carlos A Kawano-Soto, Josué Camberos-Barraza, Marco A Valdéz-Flores, Loranda Calderón-Zamora, Carla E Angulo-Rojo, Javier A Magaña-Gómez and 1 more

Abstract read
In one paragraph

Article in International journal of microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Alexis M Rodríguez-RosasPrograma de Posgrado en Ciencias Biomédicas, Facultad de Ciencias Químico-Biológicas, Universidad Autónoma de Sinaloa, Culiacán, Sinaloa, Mexico, uas.edu.mx.ORCID https://orcid.org/0000-0001-5224-0936
Diana L Baldenebro-FélixLaboratorio de Neurociencias, Facultad de Medicina, Universidad Autónoma de Sinaloa, Culiacán, Sinaloa, Mexico, uas.edu.mx.ORCID https://orcid.org/0000-0002-5746-3503
Jesús M Peréz-VillarrealPrograma de Posgrado en Ciencias Biomédicas, Facultad de Ciencias Químico-Biológicas, Universidad Autónoma de Sinaloa, Culiacán, Sinaloa, Mexico, uas.edu.mx.ORCID https://orcid.org/0000-0003-3283-562X
Jaime García-MenaDepartamento de Genética y Biología Molecular, Cinvestav, Ciudad de Mexico, Mexico, cinvestav.mx.ORCID https://orcid.org/0000-0002-0595-3711
Carlos A Kawano-SotoClínica de Geriatría, Hospital Regional Dr. Manuel Cárdenas de la Vega ISSSTE, Culiacán, Sinaloa, Mexico.
Josué Camberos-BarrazaFacultad de Medicina, Universidad Autónoma de Sinaloa, Culiacán, Sinaloa, Mexico, uas.edu.mx.ORCID https://orcid.org/0009-0003-4595-2056
Marco A Valdéz-FloresFacultad de Medicina, Universidad Autónoma de Sinaloa, Culiacán, Sinaloa, Mexico, uas.edu.mx.ORCID https://orcid.org/0000-0002-7074-6620
Loranda Calderón-ZamoraFacultad de Biología, Universidad Autónoma de Sinaloa, Culiacán, Sinaloa, Mexico, uas.edu.mx.ORCID https://orcid.org/0000-0001-7423-2283
Carla E Angulo-RojoLaboratorio de Neurociencias, Facultad de Medicina, Universidad Autónoma de Sinaloa, Culiacán, Sinaloa, Mexico, uas.edu.mx.ORCID https://orcid.org/0000-0002-5097-2444
Javier A Magaña-GómezLaboratorio de Nutrición Molecular, Facultad de Ciencias de la Nutrición y Gastronomía, Universidad Autónoma de Sinaloa, Culiacán, Sinaloa, Mexico, uas.edu.mx.ORCID https://orcid.org/0000-0003-1081-6997
Alma M Guadrón-LlanosLaboratorio de Diabetes y Comorbilidades, Facultad de Medicina, Universidad Autónoma de Sinaloa, Culiacán, Sinaloa, Mexico, uas.edu.mx.ORCID https://orcid.org/0000-0003-4782-6398

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Type 2 diabetes mellitus (T2DM) is known to increase the risk of Alzheimer's disease (AD), but the role of the gut microbiota in this relationship is not fully understood. This study investigated the gut microbiota profiles of adults with T2DM, adults with AD, both conditions (AD-T2DM), and healthy controls to identify patterns associated with metabolic and neurodegenerative conditions. Methods: A cross-sectional study was conducted with 148 participants divided into six groups: CTRL < 60 years, CTRL ≥ 60 years, T2DM < 60 years, T2DM ≥ 60 years, AD, and AD-T2DM. Clinical assessments and 16S rRNA gene sequencing of fecal samples were performed to analyze microbial diversity and composition. Results: Compared with controls, older adults with T2DM, AD, and AD-T2DM presented reduced microbial diversity and distinct microbial compositions. Notably, SCFA-producing genera ( Conclusion: This study highlights changes in the microbiota in T2DM and AD-T2DM patients, suggesting that targeting these microbial alterations could offer new prevention strategies for metabolic-neurodegenerative comorbidities. Significance Statement: T2DM and AD share metabolic and inflammatory pathways, yet their combined impact on the gut microbiota remains unexplored. By profiling 148 adults, healthy individuals, those with T2DM, AD, and co-occurring AD-T2DM, using 16S rRNA gene V4 region sequencing, we identified specific dysbiosis in AD-T2DM. Rather than examining T2DM and AD as independent conditions, the present study conceptualizes their coexistence as a metabolic-neurodegenerative interaction state and assesses whether this comorbidity is associated with a distinct gut microbiota composition and predicted functional profile. Therefore, we examine the gut microbiota of adults with AD-T2DM using an age-stratified design in an underrepresented Mexican population, integrating clinical, metabolic, cognitive, taxonomic, and functional data to explore potential mechanisms underlying metabolic-neurodegenerative crosstalk. These findings identify microbial genera that may mediate the "diabeto-neuro" crosstalk, offering novel targets for early intervention and precision microbiota-based therapies to mitigate metabolic-neurodegenerative comorbidity.

Identifiers

PMID41948549
PMCPMC13051801

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.